Role of PPARα and Its Agonist in Renal Diseases
Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, su...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2010-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2010/345098 |
id |
doaj-a817d572e3b9455f940eba9f52e6ab35 |
---|---|
record_format |
Article |
spelling |
doaj-a817d572e3b9455f940eba9f52e6ab352020-11-24T20:59:01ZengHindawi LimitedPPAR Research1687-47571687-47652010-01-01201010.1155/2010/345098345098Role of PPARα and Its Agonist in Renal DiseasesChing-Feng Cheng0Hsi-Hsien Chen1Heng Lin2Department of Medical Research, Tzu Chi General Hospital and Department of Pediatrics, Tzu Chi University, Hualien 970, TaiwanGraduate Institute of Clinical Medicine, Taipei Medical University and Department of Internal Medicine, Taipei Medical University Hospital, Taipei 110, TaiwanGraduate Institute of Pharmacology and Toxicology, Tzu Chi University, 701 Chung Yang Road, Section 3, Hualien 970, TaiwanPeroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future.http://dx.doi.org/10.1155/2010/345098 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ching-Feng Cheng Hsi-Hsien Chen Heng Lin |
spellingShingle |
Ching-Feng Cheng Hsi-Hsien Chen Heng Lin Role of PPARα and Its Agonist in Renal Diseases PPAR Research |
author_facet |
Ching-Feng Cheng Hsi-Hsien Chen Heng Lin |
author_sort |
Ching-Feng Cheng |
title |
Role of PPARα and Its Agonist in Renal Diseases |
title_short |
Role of PPARα and Its Agonist in Renal Diseases |
title_full |
Role of PPARα and Its Agonist in Renal Diseases |
title_fullStr |
Role of PPARα and Its Agonist in Renal Diseases |
title_full_unstemmed |
Role of PPARα and Its Agonist in Renal Diseases |
title_sort |
role of pparα and its agonist in renal diseases |
publisher |
Hindawi Limited |
series |
PPAR Research |
issn |
1687-4757 1687-4765 |
publishDate |
2010-01-01 |
description |
Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional benefits on endothelial function, kidney function, and anti-inflammation, suggesting that PPARα agonists may be good candidates for treating acute renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in fibric acid class, were proven to have therapeutic effects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity, and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of diabetes and inflammation-induced nephropathy. Implication of new and more potent PPAR-α activators could provide important insights into the overall benefits of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or inflammation-induced nephropathy in the future. |
url |
http://dx.doi.org/10.1155/2010/345098 |
work_keys_str_mv |
AT chingfengcheng roleofpparaanditsagonistinrenaldiseases AT hsihsienchen roleofpparaanditsagonistinrenaldiseases AT henglin roleofpparaanditsagonistinrenaldiseases |
_version_ |
1716784063396708352 |